Abstract
The discovery of some key molecular mechanisms underlying the dysregulation of the immune system responsible for inflammatory systemic diseases as severe as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), and Systemic Vasculitides, led to the development and subsequent introduction into clinical practice of biological drugs which are significantly improving the management of such complex disorders. This novel molecular targeted therapeutics represents in fact a valid alternative or complementary treatment to conventional immunosuppressive strategies, characterized by broad, unspecific actions and severe adverse effects. Main advantages of the use of biologic drugs reside in their steroid-sparing effect and in the ability of inducing remission of refractory disease states or curing specific organ involvements. Aim of this article is to review and briefly discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the canonical drugs.
Keywords: Belimumab, imatinib, infliximab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), systemic vasculitis, tocilizumab.
Current Drug Safety
Title:Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile
Volume: 11 Issue: 1
Author(s): Gianluca Moroncini, Lisa Albani, Lorenzo Nobili and Armando Gabrielli
Affiliation:
Keywords: Belimumab, imatinib, infliximab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), systemic vasculitis, tocilizumab.
Abstract: The discovery of some key molecular mechanisms underlying the dysregulation of the immune system responsible for inflammatory systemic diseases as severe as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), and Systemic Vasculitides, led to the development and subsequent introduction into clinical practice of biological drugs which are significantly improving the management of such complex disorders. This novel molecular targeted therapeutics represents in fact a valid alternative or complementary treatment to conventional immunosuppressive strategies, characterized by broad, unspecific actions and severe adverse effects. Main advantages of the use of biologic drugs reside in their steroid-sparing effect and in the ability of inducing remission of refractory disease states or curing specific organ involvements. Aim of this article is to review and briefly discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the canonical drugs.
Export Options
About this article
Cite this article as:
Moroncini Gianluca, Albani Lisa, Nobili Lorenzo and Gabrielli Armando, Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666151014115251
DOI https://dx.doi.org/10.2174/1574886310666151014115251 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ABC Transporters and Drug Resistance in Patients with Epilepsy
Current Pharmaceutical Design Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Application of Non-flavonoid Phenolics in Diabetes: Antiinflammatory Effects
Current Medicinal Chemistry Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology The Use of Colchicine in Respiratory Diseases
Current Respiratory Medicine Reviews A Study of the Relaxed Mechanisms Induced by Novokinin in the Isolated Porcine Coronary Artery Ring Segments
Protein & Peptide Letters Green Tea from the Far East to the Drug Store: Focus on the Beneficial Cardiovascular Effects
Current Pharmaceutical Design Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Exercise Induced Cardioprotection: An Overview of a Unique Form of Preconditioning
Current Cardiology Reviews Nitric Oxide is a Central Common Metabolite in Vascular Dysfunction Associated with Diseases of Human Pregnancy
Current Vascular Pharmacology Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Beneficial Role of Vitexin and Isovitexin Flavonoids in the Vascular Endothelium and Cardiovascular System
Current Nutraceuticals Subject Index to Volume 10
Current Pharmaceutical Design Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Haptoglobin Phenotype Correlates with the Extent of Cerebral Deep White Matter Lesions in Hypertensive Patients
Current Neurovascular Research The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Current Vascular Pharmacology Vaccination Against High Blood Pressure
Current Pharmaceutical Design Meet Our Co-Editor
Current Vascular Pharmacology Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design